AI Score

Unlock

Arbutus Biopharma Corpora... (ABUS)

AI Score

Unlock

3.50

0.00 (0.00%)

At close: Mar 31, 2025, 3:59 PM

3.49

-0.15%

After-hours: Mar 31, 2025, 05:02 PM EDT

0.00% (1D)

Bid	3.25
Market Cap	670.18M
Revenue (ttm)	6.76M
Net Income (ttm)	-76.9M
EPS (ttm)	-0.38
PE Ratio (ttm)	-9.21
Forward PE	-7.13
Analyst	Buy

Ask	3.54
Volume	967,262
Avg. Volume (20D)	946,074.1
Open	3.46
Previous Close	3.50
Day's Range	3.35 - 3.54
52-Week Range	2.30 - 4.72
Beta	1.93

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 26, 2007

Employees 44

Stock Exchange NASDAQ

Ticker Symbol ABUS

Website https://www.arbutusbio.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 42.86% from the latest price.

Stock Forecasts

Earnings Surprise

Arbutus Biopharma has released their quartely earnings on Mar 27, 2025:

Revenue of $1.57M misses estimates by $636K, with -26.62% YoY decline.

EPS of -0.07 exceeds estimates by 0.05, with 41.67% YoY growth.

Next Earnings Release

Arbutus Biopharma Corporation is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 days ago

+7.03%

Arbutus Biopharma shares are trading higher on pos... Unlock content with Pro Subscription

4 months ago

+0.28%

Barinthus Biotherapeutics shares are trading lower. The company announced data from the ongoing Phase 2b HBV003 clinical trial.

News

8 hours ago · zacks.com

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Just now · zacks.com

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

4 days ago · zacks.com

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago.

1 week ago · businesswire.com

GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (...

2 months ago · seekingalpha.com

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19 ...

2 months ago · seekingalpha.com

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Company's phase 2a trial of Imdusiran with pegylated interferon alfa-2a achieved a functional cure in 25% of Hepatitis B patients. The company is developing its own in-house oral PD-L1 inhibitor, AB-1...